Arakelov S, Gorny M K, Williams C, Riggin C H, Brady F, Collett M S, Zolla-Pazner S
Department of Pathology, New York University Medical Center, New York.
J Infect Dis. 1993 Sep;168(3):580-5. doi: 10.1093/infdis/168.3.580.
The prevalence of IgG antibodies to human B19 parvovirus (anti-B19) is elevated in individuals infected with human immunodeficiency virus (HIV), especially during the later stages of HIV infection. In subjects with high titers of IgG anti-B19, 86% (19 of 22) had circulating B cells producing anti-B19. Immortalization of these cells with Epstein-Barr virus and generation of heterohybridomas by fusion with a mouse X human heteromyeloma resulted in the production of two cell lines producing IgG1 kappa monoclonal antibodies (MAbs). Both of these MAbs were specific for conformational epitopes on the VP2 capsid protein of B19 parvovirus and both were capable of neutralizing 50% of the viral infectivity in a human erythroid colony-forming unit assay at < or = 1 micrograms of MAb/mL. These human MAbs are potentially useful in the treatment of acute B19 parvovirus infection.
在感染人类免疫缺陷病毒（HIV）的个体中，尤其是在HIV感染后期，针对人细小病毒B19的IgG抗体（抗B19）的流行率会升高。在IgG抗B19高滴度的受试者中，86%（22例中的19例）有循环B细胞产生抗B19。用爱泼斯坦-巴尔病毒使这些细胞永生化，并通过与小鼠X人异骨髓瘤融合产生异源杂交瘤，从而产生了两个产生IgG1 κ单克隆抗体（MAb）的细胞系。这两种MAb均对细小病毒B19的VP2衣壳蛋白上的构象表位具有特异性，并且在人红细胞集落形成单位试验中，当MAb浓度≤1μg/mL时，两者均能够中和50%的病毒感染性。这些人源MAb在治疗急性细小病毒B19感染方面可能具有潜在用途。
